bromocriptine

(redirected from Cycloset)
Also found in: Dictionary, Encyclopedia.
Related to Cycloset: bromocriptine

bromocriptine

 [bro″mo-krip´tēn]
an ergot alkaloid that acts as a dopamine agonist; used as the mesylate salt to suppress prolactin secretion in the treatment of pituitary prolactinomas and of hyperprolactinemia-associated amenorrhea, galactorrhea, infertility, or male hypogonadism. It is also used as an antidyskinetic, usually in conjunction with levodopa, in the treatment of parkinsonism, and is used as a growth hormone suppressant in the treatment of acromegaly. Administered orally.

bromocriptine

/bro·mo·crip·tine/ (bro″mo-krip´tēn) an ergot alkaloid dopamine agonist, used as the mesylate salt to suppress prolactin secretion and thereby treat prolactinomas and endocrine disorders secondary to hyperprolactinemia; also used as an antidyskinetic in parkinsonism and a growth hormone suppressant in acromegaly.

bromocriptine

(brō′mō-krĭp′tēn)
n.
An ergot alkaloid, C32H40BrN5O5, that is a dopamine antagonist and is used in its mesylate form to treat Parkinson's disease, acromegaly, and excessive prolactin secretion, and to reduce the size of certain pituitary tumors.

bromocriptine

Endocrinology
An ergoline derivative which reduces pituitary prolactin secretion and size of pituitary tumours.
 
Indications
Hyperprolactinemia, pituitary tumours, amenorrhoea, female infertility, hypogonadism, acromegaly, Parkinson’s disease, neuroleptic malignant syndrome, type-2 diabetes.
 
Adverse effects
Orthostatic hypotension, vomiting, vertigo, headaches, upset stomach, coronary vasospasm, pulmonary fibrosis, hepatotoxicity.

Immunology
A dopamine D2-receptor inhibitor which inhibits T-cell-dependent induction of macrophage tumouricidal activity.

bromocriptine

An ERGOT derivative drug with DOPAMINE-like effects. It is used in the treatment of PARKINSON'S DISEASE and ACROMEGALY and given to prevent LACTATION by inhibiting the secretion of the hormone prolactin by the pituitary gland. A brand name is Parlodel.

Bromocriptine

Also known as Parlodel, the main drug used to treat galactorrhea by reducing levels of the hormone prolactin.
Mentioned in: Galactorrhea, Lactation

bromocriptine

a dopamine agonist; as a derivative of ergot alkaloids it is a luteolytic and arbortifacient which suppresses prolactin secretion and lowers plasma ACTH levels. Used as an abortifacient and in the treatment of pituitary-dependent hyperadrenocorticism.
References in periodicals archive ?
Cycloset is the first drug to win FDA approval under new guidelines that require better evidence that diabetes treatments are heart-safe.
People don't have those seasonal variations but the theory is the dopamine plays a role anyway in sensitivity to insulin, although Cycloset apparently did not affect weight.
CYCLOSET is a prescription drug approved by the US Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.
A 24-week, placebo-controlled, monotherapy study of the impact of CYCLOSET on glycemic control in 159 overweight adults with Type 2 diabetes and baseline HbA1c of 7.
Additional data from a prospective 24-week assessment of the efficacy of CYCLOSET in improving glycemic control in Type 2 diabetes, patients poorly controlled on one or two oral anti-diabetes agents indicated that 35% - 40% of patients reached an HbA1c goal of equal or lower than 7% with CYCLOSET versus approximately 10% of placebo treated patients.
Charles Sutphin, co-chairman, president and chief executive officer of S2 Therapeutics said, that the company is excited about the distribution and license agreement with Santarus for CYCLOSET and the strategic fit with its organisation.
Additionally, among the EPP population with no concomitant change in diabetes medication, treatment with CYCLOSET resulted in:
0 in the CYCLOSET treated groups compared with placebo (32%-42% vs 5%-7%, respectively) (p<0.
These poorly controlled patients were randomized 2:1 to CYCLOSET add-on (1.
CYCLOSET is a unique, quick release form of bromocriptine, a dopamine D2 receptor agonist, and is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
The new analyses published in JAHA investigated 1) the impact of CYCLOSET on the ischemic cardiovascular composite endpoint of myocardial infarction, stroke, and cardiovascular death (major adverse cardiovascular events; MACE) and 2) cardiovascular death as a component of a new composite cardiovascular endpoint (myocardial infarction, stroke, hospitalization for unstable angina, hospitalization for congestive heart failure, coronary revascularization and cardiovascular death) to more critically evaluate the impact of CYCLOSET on cardiovascular outcomes in the study population.
4 million for the second quarter of 2012 included royalties on GLUMETZA net sales under the restructured commercialization agreement signed in August 2011, the gross margin split on CYCLOSET net sales, royalties on ZEGERID net sales and amortization of upfront payments.